AIFinancial Timesabout 1 hour ago
Insilico Nominates ISM9077 as Preclinical Candidate
1 min read
Insilico Medicine nominated ISM9077, a potential first-in-class Target Y inhibitor, as a preclinical candidate for ocular diseases, inflammatory disorders, and aging. The AI-empowered pipeline-in-a-drug option advances the company's drug discovery efforts.
Level
Hype check
Tap to vote and see what everyone thinks.
Summary by ByteBrief
